CN104758860B - A kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome - Google Patents
A kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome Download PDFInfo
- Publication number
- CN104758860B CN104758860B CN201510211910.9A CN201510211910A CN104758860B CN 104758860 B CN104758860 B CN 104758860B CN 201510211910 A CN201510211910 A CN 201510211910A CN 104758860 B CN104758860 B CN 104758860B
- Authority
- CN
- China
- Prior art keywords
- parts
- liquid
- filtrate
- weight
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 36
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 36
- 208000006673 asthma Diseases 0.000 title claims abstract description 35
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 27
- 241000218394 Magnolia liliiflora Species 0.000 claims abstract description 37
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 37
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 37
- 241000005787 Cistanche Species 0.000 claims abstract description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 31
- 239000011780 sodium chloride Substances 0.000 claims abstract description 31
- 239000000463 material Substances 0.000 claims abstract description 26
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 25
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 25
- 241000490229 Eucephalus Species 0.000 claims abstract description 25
- 241000249864 Tussilago Species 0.000 claims abstract description 25
- 125000003118 aryl group Chemical group 0.000 claims abstract description 25
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 25
- 235000013976 turmeric Nutrition 0.000 claims abstract description 25
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 24
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 24
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 24
- 244000250129 Trigonella foenum graecum Species 0.000 claims abstract description 24
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims abstract description 24
- 241001251949 Xanthium sibiricum Species 0.000 claims abstract description 24
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims abstract description 24
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 23
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- 239000007788 liquid Substances 0.000 claims description 56
- 239000000706 filtrate Substances 0.000 claims description 44
- 238000001914 filtration Methods 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 21
- 239000006071 cream Substances 0.000 claims description 16
- 230000006837 decompression Effects 0.000 claims description 16
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 235000013372 meat Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- -1 is mixed Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 2
- 241001415959 Grus japonensis Species 0.000 claims 1
- 235000019082 Osmanthus Nutrition 0.000 claims 1
- 241000333181 Osmanthus Species 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 229940126678 chinese medicines Drugs 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 206010039101 Rhinorrhoea Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000013123 lung function test Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010010970 Cor pulmonale chronic Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000497005 Ixophorus unisetus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000296102 Selinum monnieri Species 0.000 description 1
- 235000019084 Selinum monnieri Nutrition 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 206010042241 Stridor Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940106779 montelukast 10 mg Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the Chinese medicine composition for the treatment of allergic rhinitis Asthma Syndrome, can effectively solve the problems, such as the medication of allergic rhinitis Asthma Syndrome, its technical scheme solved is made up of the material medicine of following parts by weight meter：5 25 parts of American Ginseng, 20 40 parts of HERBA EPIMEDII, 10 30 parts of saline cistanche, 10 30 parts of frutus cnidii, 10 30 parts of fenugreek, 20 40 parts of rhizoma pinellinae praeparata, 20 40 parts of aster, 10 30 parts of tussilago, 10 30 parts of Fructus Corni, windproof 10 30 parts, 10 30 parts of the achene of Siberian cocklebur, 20 40 parts of the flower bud of lily magnolia, 20 40 parts of cassia twig, 10 30 parts of root tuber of aromatic turmeric, 20 40 parts of rattletop, 10 30 parts of Ligusticum wallichii, 10 30 parts of 10 30 parts of hairyvein agrimony and radix glycyrrhizae, traditional Chinese medicine composite of the present invention is enriched, simple production process, drug safety, it is reliable and stable, good effect, it is the active drug for treating allergic rhinitis Asthma Syndrome, one for the field of Chinese medicines innovates greatly.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome.
Background technology
Allergic rhinitis (AR) and bronchial astehma (BA) have been classified as 21 century global health problem, are global morbidities
Rate rises most fast disease.Allergic rhinitis Asthma Syndrome (CARAS) is world's allergy tissue (WAO) proposition in recent years
New medical diagnosis term, refer to clinical or subclinical upper respiratory tract allergy (allergic rhinitis) and lower breathing occur simultaneously
The allergic conditions (asthma) in road, both often simultaneously and deposit.Epidemiology survey confirms that asthma is sent out in Allergic Rhinitis
Sick rate is high compared with normal person 4-20 times, and the asthma incidence of disease is about 2%-5% in normal population.Research in recent years shows, 70%-90%
Asthmatics with allergic rhinitis；40%-50% allergic rhinitis occurs together bronchial astehma.It is even it is believed that super
Asthma may be developed into or with lower respiratory tract symptom by crossing 60% allergic rhinitis.
At present treatment allergic rhinitis asthmatic syndrome Western medicine mainly with inhaled, take antihistamine etc.
Based on, the drug therapy CARAS such as hormone high recurrence rates, side effect are big, and inconvenience is long-term use of.Chinese medicine allergic rhinitis is roared
Asthma syndrome shows the superiority of uniqueness in clinical practice, turns into the focus of the current area research.It is substantial amounts of clinical and
Experimental study fully confirms, on the basis of traditional western medicine plus carries out Coryza Treated by Syndrome Differentiation with Chinese medicine and is improving curative effect, reduces west
Medicine adverse reaction, Western medicine dosage is reduced, reduce recurrence rate etc. and play a significant role.
Existing " one kind treats compound medicine of allergic rhinitis-Asthma Syndrome and its preparation method and application ", patent
Application number：201210326783.3 the compound medicine is applied to CARAS lung qi virtual loss, wind phlegm resistance lung card.CARAS is clinical at present
Medication can not meet that many patients are actually needed to treatment CARAS, and New drug discovery is imperative.Allergic rhinitis is treated to roar
The development and application for breathing heavily the Chinese medicine of syndrome is still current urgent problem.
The content of the invention
For the above situation, to solve the defect of prior art, the purpose of the present invention is just to provide one kind and treats anaphylaxis
The Chinese medicine composition of rhinitis Asthma Syndrome, can effectively solve the problems, such as the medication of allergic rhinitis Asthma Syndrome.
Allergic rhinitis Asthma Syndrome belongs to traditional Chinese medicine " allergic rhinitis ", " card of roaring " category.Its pathogenesis is physically weak evil criminal,
Lung Qi obstruction is caused, volt phlegm is detained, sent out to have a stuffy nose, stridulating, and it is void, is designated as reality, therefore tonifying lung spleen kidney is focused on when taking stopgap measures, and is controlled
Suitable lowering the adverse-rising QI to resolve phlegm is relievingd asthma, and strengthening spleen, tonifying kidney supports lung.Accordingly, the technical scheme that the present invention solves is to be by following parts by weight meter
Material medicine is made：American Ginseng 5-25 parts, HERBA EPIMEDII 20-40 parts, saline cistanche 10-30 parts, frutus cnidii 10-30 parts, fenugreek 10-
30 parts, rhizoma pinellinae praeparata 20-40 parts, aster 20-40 parts, tussilago 10-30 parts, Fructus Corni 10-30 parts, windproof 10-30 parts, the achene of Siberian cocklebur
10-30 parts, flower bud of lily magnolia 20-40 parts, cassia twig 20-40 parts, root tuber of aromatic turmeric 10-30 parts, rattletop 20-40 parts, Ligusticum wallichii 10-30 parts, hairyvein agrimony 10-
30 parts and radix glycyrrhizae 10-30 parts, American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia are mixed, and add American Ginseng, HERBA EPIMEDII, meat
The ethanol that desert cistanche, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%, heating and refluxing extraction 2 hours, filtering, obtains the first filtrate, and first
Decompression filtrate recycling ethanol, decoction is obtained, and be concentrated into the 1/2-1/3 of original volume, A liquid is made；The dregs of a decoction after ethanol is extracted again
With frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, the windproof, achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, celestial being
Crane grass, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct twice, 1.5 hours every time, collecting decoction, filtering,
The second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, B liquid is made, and then mixes A liquid and B liquid, concentration
Relative density is 1.10-1.30 clear cream (medicinal extract) to 50 DEG C, the 20-60% of clear cream weight auxiliary material is added, according to medicine
Chinese medicinal composition preparation clinically is made in preparation customary preparation methods；Described auxiliary material be sucrose, starch, dextrin, talcum powder,
Magnesium stearate, calcium sulfate, Steviosin one or more kinds of composition therein, described Chinese medicinal composition preparation are capsule
Agent, pill, granule, one kind of tablet or oral liquid.
Traditional Chinese medicine composite of the present invention is enriched, simple production process, and drug safety is reliable and stable, good effect, is treatment
The active drug of allergic rhinitis Asthma Syndrome, it is that the one of the field of Chinese medicines innovates greatly.
Embodiment
The embodiment of the present invention is described in further detail with reference to embodiments.
Embodiment 1
In the specific implementation, Chinese medicine composition of the present invention can be made up of the material medicine of following parts by weight meter：American Ginseng
10 parts, 20 parts of HERBA EPIMEDII, 15 parts of saline cistanche, 15 parts of frutus cnidii, 15 parts of fenugreek, 25 parts of rhizoma pinellinae praeparata, 25 parts of aster, tussilago 15
Part, Fructus Corni 15, windproof 15 parts, 15 parts of the achene of Siberian cocklebur, 25 parts of the flower bud of lily magnolia, 20 parts of cassia twig, 15 parts of root tuber of aromatic turmeric, 25 parts of rattletop, 15 parts of Ligusticum wallichii,
10 parts of 15 parts of hairyvein agrimony and radix glycyrrhizae, American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia are mixed, add American Ginseng, HERBA EPIMEDII,
The ethanol that saline cistanche, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%, heating and refluxing extraction 2 hours, filtering, obtains the first filtrate, the
One decompression filtrate recycling ethanol, decoction is obtained, and be concentrated into the 1/2-1/3 of original volume, A liquid is made；Medicine after ethanol is extracted again
Slag and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, the windproof, achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii,
Hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct twice, 1.5 hours every time, collecting decoction, mistake
Filter, obtains the second filtrate, and the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, and B liquid is made, and then mixes A liquid and B liquid, dense
The clear cream (medicinal extract) that relative density at 50 DEG C is 1.10-1.30 is reduced to, the 20-60% of clear cream weight auxiliary material is added, according to medicine
Thing preparation conventional method makes Chinese medicinal composition preparation clinically；Described auxiliary material is sucrose, starch, dextrin, talcum powder, hard
Fatty acid magnesium, calcium sulfate, Steviosin one or more kinds of composition therein, described Chinese medicinal composition preparation are capsule
Agent, pill, granule, one kind of tablet or oral liquid.
Embodiment 2
The preparation method of granule specifically follows the steps below：
(1) each material medicine is weighed respectively by following weight：American Ginseng 100g, HERBA EPIMEDII 200g, saline cistanche 150g, cnidium monnieri
Sub- 150g, fenugreek 150g, rhizoma pinellinae praeparata 250g, aster 250g, tussilago 150g, Fructus Corni 150g, windproof 150g, the achene of Siberian cocklebur
150g, flower bud of lily magnolia 250g, cassia twig 200g, root tuber of aromatic turmeric 150g, rattletop 250g, Ligusticum wallichii 150g, hairyvein agrimony 150g and radix glycyrrhizae 100g；
(2) American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, adds American Ginseng, HERBA EPIMEDII, meat desert
The ethanol that Rong, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%, heating and refluxing extraction 2 hours, filtering, obtain the first filtrate, the first filter
Ethanol is recovered under reduced pressure in liquid, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, and A liquid is made；
(3) dregs of a decoction after ethanol is extracted and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, it is windproof,
The achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct two
It is secondary, 1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, system
Into B liquid；
(4) A liquid and B liquid are mixed, are concentrated at 50 DEG C, relative density is 1.10 clear cream, adds sucrose and dextrin, is mixed
It is even, particle is made, dries, produces.
Embodiment 3
The preparation method of tablet specifically follows the steps below：
(1) each raw material is weighed respectively by following weight：American Ginseng 50g, HERBA EPIMEDII 400g, saline cistanche 100g, frutus cnidii
300g, fenugreek 100g, rhizoma pinellinae praeparata 400g, aster 200g, tussilago 300g, Fructus Corni 100g, windproof 300g, the achene of Siberian cocklebur
100g, flower bud of lily magnolia 400g, cassia twig 200g, root tuber of aromatic turmeric 300g, rattletop 200g, Ligusticum wallichii 300g, hairyvein agrimony 100g and radix glycyrrhizae 300g；
(2) American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, adds American Ginseng, HERBA EPIMEDII, meat desert
The ethanol that Rong, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%, heating and refluxing extraction 2 hours, filtering, obtain the first filtrate, the first filter
Ethanol is recovered under reduced pressure in liquid, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, and A liquid is made；
(3) dregs of a decoction after ethanol is extracted and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, it is windproof,
The achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct two
It is secondary, 1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, system
Into B liquid；
(4) A liquid and B liquid are mixed, are concentrated at 50 DEG C, relative density is 1.30 clear cream, adds starch and mixes, does
It is dry, crush, add talcum powder and magnesium stearate, mixing is tabletted, every weight 0.5g.
Embodiment 4
The preparation method of capsule specifically follows the steps below：
(1) each raw material is weighed respectively by following weight：American Ginseng 250g, HERBA EPIMEDII 200g, saline cistanche 300g, frutus cnidii
100g, fenugreek 300g, rhizoma pinellinae praeparata 200g, aster 400g, tussilago 100g, Fructus Corni 300g, windproof 100g, the achene of Siberian cocklebur
300g, flower bud of lily magnolia 200g, cassia twig 400g, root tuber of aromatic turmeric 100g, rattletop 400g, Ligusticum wallichii 100g, hairyvein agrimony 300g and radix glycyrrhizae 100g；
(2) American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, adds American Ginseng, HERBA EPIMEDII, meat desert
The ethanol that Rong, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%, heating and refluxing extraction 2 hours, filtering, obtain the first filtrate, the first filter
Ethanol is recovered under reduced pressure in liquid, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, and A liquid is made；
(3) dregs of a decoction after ethanol is extracted and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, it is windproof,
The achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct two
It is secondary, 1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, system
Into B liquid；
(4) A liquid and B liquid are mixed, are concentrated into the clear cream that relative density at 50 DEG C is 1.20, added starch and mix, dry,
Crush, add calcium sulfate and talcum powder, mix, particle is made, load capsule, every weight 0.5g.
Embodiment 5
The preparation method of pill specifically follows the steps below：
(1) each raw material is weighed respectively by following weight：American Ginseng 200g, HERBA EPIMEDII 350g, saline cistanche 200g, frutus cnidii
200g, fenugreek 200g, rhizoma pinellinae praeparata 300g, aster 300g, tussilago 200g, Fructus Corni 250g, windproof 250g, the achene of Siberian cocklebur
250g, flower bud of lily magnolia 300g, cassia twig 300g, root tuber of aromatic turmeric 250g, rattletop 300g, Ligusticum wallichii 200g, hairyvein agrimony 250g and radix glycyrrhizae 200g；
(2) American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, adds American Ginseng, HERBA EPIMEDII, meat desert
The ethanol that Rong, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%, heating and refluxing extraction 2 hours, filtering, obtain the first filtrate, the first filter
Ethanol is recovered under reduced pressure in liquid, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, and A liquid is made；
(3) dregs of a decoction after ethanol is extracted and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, it is windproof,
The achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct two
It is secondary, 1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, system
Into B liquid；
(4) A liquid and B liquid are mixed, are concentrated into the clear cream that relative density at 50 DEG C is 1.20, added starch and mix, dry,
Crush, add sucrose and talcum powder, mix, pill is made, the weight 0.5g per ball.
For allergic rhinitis Asthma Syndrome clinical symptoms diversity, pathogenetic complexity, the present invention based on
The principle of organic conception and diagnosis and treatment, using individualized treatment as characteristic, treated from Mutiple Targets, too many levels, multipath expansion,
Chinese medicine composition of the present invention has rapid-action, curative for effect, safe and reliable in clinical practice, can be obviously improved allergic rhinitis heavy breathing
The advantages such as the occurrence and development of syndrome patient's patient's condition are breathed heavily, there is wide potential applicability in clinical practice, and achieve through clinical test
Satisfied effect, relevant testing data are as follows：
Case scenario
Select in March, 2012 in September, 2013 our hospital's treat-and-release 86 allergic rhinitis Asthma Syndrome patients,
It is age 20-65 year, average 32.5 years old；The course of disease is -4 years 6 months, average 28 months.Patient is randomly divided into two groups：Experimental group 43
Example, control group 43.Control group and experimental group patient are in age and the course of disease and the order of severity etc. no significant difference (P>
0.05)。
1. diagnostic criteria
1.1 Western medicine diagnostic criteria
(1) allergic rhinitis, light, the moderate diagnostic criteria of bronchial astehma (stage of attack)：WHO is respectively referred in 2001
Relevant criterion in the allergic rhinitis diagnosis and treatment standard of formulation and 08 edition " global asthma preventing and treating is proposed " (GINA).(2) breathe heavily
Cease, cough, coughing up phlegm, the state of an illness of wheezing sound symptom and sign and the degree criteria for classifying are formulated for 1993 with reference to health ministry bureau of drug administration
" Chinese medicine (new drug) guideline of clinical investigations " in relevant criterion.
1.2 tcm diagnosis standard
Reference《Traditional Chinese and western medicine clinic respirology》(China Traditional Chinese Medicine Publishing House, 98 years), " Chinese medicine developed and published in 2002
Clinical Researches of New Drugs guideline ", " Chinese medical disease Standardization of diagnosis and curative effect " lung deficiency of the kidney void of nineteen ninety-five implementation, wind phlegm resistance lung card：
Primary symptom：Sneeze, asthma, uncomfortable in chest, laryngeal stridor；Secondary disease：1. have a stuffy nose, cough up white foam phlegm；2. aversion to cold and cold limbs, easy catching a cold；3. cough, chest
Suppress turgor；4. pale tongue with white fur, deep thready pulse.Possess primary symptom and binomial (or more than 2) secondary disease person is i.e. diagnosable.
1.3 case inclusive criterias
(1) diagnosis of all doctors trained in Western medicine meet simultaneously allergic rhinitis, bronchial astehma (stage of attack, chronic sustained phase) it is light, (II
Level), the patient of moderate (III grade) diagnostic criteria；(2) patient that Chinese medical discrimination category lung deficiency of the kidney is empty, wind phlegm hinders lung；(3) age exists
Person between 20-65 year；(4) informed consent.
1.4 case exclusion standards (including inadaptable card and rejecting standard)
(1) severe asthma (or status asthmaticus)；(2) chronic cor pulmonale (heart function decompensation
Phase)；(3) confirm on inspection by the chronic patient that pants caused by the factors such as tuberculosis fungi, tumour；(4) it is associated with angiocarpy, liver,
The severe primary disease such as kidney and hemopoietic system, mental patient；(5) pregnant woman or women breast-feeding their children；(6) all do not meet includes mark
Standard, not by regulation medication, it can not judge curative effect or data does not affect the treatment judgement person entirely.
2. test method
2.1 group technology：This research use (RCT methods) is random, check experiment is observed, and experiment disease is included to above-mentioned
Example uses random pair group technology, treatment group and control group is found on random table, and ensure two groups of cases in severity extent
And sex, age, the course of disease etc. no difference of science of statistics (P>0.05).
2.2 therapeutic scheme
Control group (single use of western medicine group):Via intranasal application inhalation of budesonide aerosol 400 μ g, 2 times/d, while oral Meng Lusi
Special 10mg, 1 time/d, 2 weeks/course for the treatment of.
Experimental group (shares Chinese medicine group):Conventional therapy (via intranasal application inhalation of budesonide aerosol 400 μ g, 2 times/d, together
When time oral montelukast 10mg, 1 time/d) while, Chinese medicine composition prepared by oral the inventive method, 10g/ times, 3 times/day,
2 weeks/course for the treatment of.
3. curative effect judge index
3.1 sniffle is classified scoring criteria:Change according to the revision in 1997 of Otolaryngology branch of Chinese Medical Association
Answering property rhinitis examines standard and efficacy assessment standard:1 point:Sneeze continuous 3-9, runny nose blows nose≤4 time daily, occasionally there is nasal obstruction,
Disconnected rhiocnesmus；2 points:Sneeze continuous 10-14, runny nose blows nose 5-9 times daily, usually has a stuffy nose, and rhiocnesmus ant row sense but can endure；3 points:
Sneeze is continuous >=and 15, runny nose blows nose >=15 time daily, and lasting nasal obstruction, the sense of rhiocnesmus ant row is unbearably；Asymptomatic 0 point of note.According to
Upper standard, by doctor, rear each judgement is scored once before the treatment.
3.2 chest symptom score evaluation criteria:0 point:Without any symptom, all activities can be participated in；1 point:Pant and send out weekly
Make<2 times or suction relax pant weekly>2 times, heavy physical labour can not be participated in, night there are light symptoms but do not influence to sleep；2 points:
Pant and break out weekly>2 times or suction albuterol>2 times, daily routines have symptom, and night is waken up with a start by symptom often；3 points:Asthma
Breath is daily or persistently breaks out, and stiff, night-time attack frequently has difficulty in going to sleep.According to above standard, by doctor before the treatment after
It is each to judge to score once.
3.3 lung function tests:Lung function tests is carried out using lung function instrument (HI-198 types, Chest companies), no matter treated
Front and rear, 12h disables respective medicine to two groups of patients before detection.In view of the age of patient, height, sex and weight can influence
The absolute value of PFT, thus surveyed the 1st second forced expiratory volume (FEV1) result represented with the percentage of predicted value.This
Text is according to the MAIN OUTCOME MEASURES of FEV1% and maximum expiratory flow rate (PEFR) as PFT.
3.4 measurement of bronchial responsiveness:Treated respectively using measurement of bronchial responsiveness instrument (TCK6100 types, Chest companies)
It is front and rear to be measured with sucking gradually the histamine of progressive concentration, made with respiratory resistance at initial stage (Rrs.c) and the threshold of reaction (Dmin)
For observation index.
4. result
Comparative result between the pretherapy and post-treatment symptom score of 4.1 two groups of patients and group
After drug therapy by 1 course for the treatment of, treatment group is substantially better than pair in terms of sniffle and chest symptom is improved
According to group (P<0.01), it is shown in Table 1.
Results contrast between pretherapy and post-treatment group of patient of 1 two groups of table
Note:The aP compared with before treatment<0.05,bP<0.01；The aP compared with control group<0.05,bP<0.05.
The pretherapy and post-treatment pulmonary ventilation function testing result of 4.2 two groups of patients
After drug therapy by 1 course for the treatment of, treatment group and control group can significantly improve the pulmonary ventilation work(of asthmatic patient
Can, pretherapy and post-treatment the 1st second forced expiratory volume (FEV1) and the statistically significant (P of maximum expiratory flow rate (PEFR) difference<
0.01).Compare the statistically significant (P of PEFR differences between two groups<0.05) 2, are shown in Table.
The pretherapy and post-treatment pulmonary ventilation function detected value of 2 two groups of patients of table
Note:The aP compared with before treatment<0.05,bP<0.01；The cP compared with control group<0.05.
The pretherapy and post-treatment measurement of bronchial responsiveness result of 4.3 two groups of patients
After drug therapy by 1 course for the treatment of, treatment group and control group respiratory resistance at initial stage (Rrs.c) and the threshold of reaction
(Dmin) can significantly improve, the statistically significant (P of difference<0.01), the statistically significant (P of Dmin differences is compared between two groups<
0.05) table 3, is referred to.
The pretherapy and post-treatment measurement of bronchial responsiveness results contrast of 3 two groups of patients of table
Note:The aP compared with before treatment<0.01,bP<0.01；The cP compared with control group<0.05.
Follow-up situation recurs 7 to 86 allergic rhinitis Asthma Syndrome follow-up of patients 1 year after sharing the treatment of Chinese medicine group
Example (16.3%), Western medicine decrement person 32, stops user 7 completely；36 (83.7%) are recurred after the treatment of single use of western medicine group, control
Group and treatment group compare recurrence rate significant difference (P<0.05).Share the secondary digestive tract ulcer of Chinese medicine group, allergic rash,
Deng adverse reaction totally 3, alone hormone group 11, both significant difference (P<0.05).
Traditional Chinese medicine composite of the present invention is enriched, simple production process, and drug safety is reliable and stable, good effect, is treatment
The active drug of allergic rhinitis Asthma Syndrome, it is that the one of the field of Chinese medicines innovates greatly, there is actual clinical meaning.
Claims (6)
1. a kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome, it is characterised in that be by following parts by weight meter
Material medicine be made：American Ginseng 5-25 parts, HERBA EPIMEDII 20-40 parts, saline cistanche 10-30 parts, frutus cnidii 10-30 parts, fenugreek
It is 10-30 parts, rhizoma pinellinae praeparata 20-40 parts, aster 20-40 parts, tussilago 10-30 parts, Fructus Corni 10-30 parts, windproof 10-30 parts, grey
Ears or side handles of a utensil 10-30 parts, flower bud of lily magnolia 20-40 parts, cassia twig 20-40 parts, root tuber of aromatic turmeric 10-30 parts, rattletop 20-40 parts, Ligusticum wallichii 10-30 parts, red crowned crane
Careless 10-30 parts and radix glycyrrhizae 10-30 parts, American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia are mixed, and add American Ginseng, celestial spirit
The ethanol that spleen, saline cistanche, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%, heating and refluxing extraction 2 hours, filtering, obtains the first filtrate,
First decompression filtrate recycling ethanol, decoction is obtained, and be concentrated into the 1/2-1/3 of original volume, A liquid is made；After ethanol is extracted again
The dregs of a decoction and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, the windproof, achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, river
Rhizome of chuanxiong, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct twice, 1.5 hours every time, collecting decoction,
Filtering, obtains the second filtrate, and the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, and B liquid is made, and then mixes A liquid and B liquid,
The clear cream that relative density at 50 DEG C is 1.10-1.30 is concentrated into, the 20-60% of clear cream weight auxiliary material is added, according to pharmaceutical preparation
Chinese medicinal composition preparation clinically is made in customary preparation methods；Described auxiliary material is sucrose, starch, dextrin, talcum powder, tristearin
Sour magnesium, calcium sulfate, Steviosin one or more kinds of composition therein, described Chinese medicinal composition preparation be capsule,
Pill, granule, one kind of tablet or oral liquid.
2. it is according to claim 1 treatment allergic rhinitis Asthma Syndrome Chinese medicine composition, it is characterised in that by with
The material medicine of lower parts by weight meter is made：10 parts of American Ginseng, 20 parts of HERBA EPIMEDII, 15 parts of saline cistanche, 15 parts of frutus cnidii, fenugreek
15 parts, 25 parts of rhizoma pinellinae praeparata, 25 parts of aster, 15 parts of tussilago, Fructus Corni 15, windproof 15 parts, 15 parts of the achene of Siberian cocklebur, 25 parts of the flower bud of lily magnolia, osmanthus
10 parts of 20 parts of branch, 15 parts of root tuber of aromatic turmeric, 25 parts of rattletop, 15 parts of Ligusticum wallichii, 15 parts of hairyvein agrimony and radix glycyrrhizae, by American Ginseng, HERBA EPIMEDII, meat desert
Rong, the flower bud of lily magnolia mix, and add the ethanol that American Ginseng, HERBA EPIMEDII, saline cistanche, the mass concentration of 8 times of weight of the flower bud of lily magnolia are 75%,
Heating and refluxing extraction 2 hours, filtering, obtains the first filtrate, the first decompression filtrate recycling ethanol, obtains decoction, and be concentrated into original volume
1/2-1/3, A liquid is made；The dregs of a decoction and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, mountain Zhu after ethanol is extracted again
Cornel, the windproof, achene of Siberian cocklebur, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add 6 times of weight of material medicine
Water, decoct twice, 1.5 hours every time, collecting decoction, filtering, obtain the second filtrate, the second filtrate decompression is concentrated into the 1/ of original volume
2-1/3, B liquid is made, then mixes A liquid and B liquid, be concentrated into the clear cream that relative density at 50 DEG C is 1.10-1.30, add clear
The 20-60% of cream weight auxiliary material, Chinese medicinal composition preparation clinically is made according to pharmaceutical preparation conventional method；Described is auxiliary
Expect for sucrose, starch, dextrin, talcum powder, magnesium stearate, calcium sulfate, Steviosin one or more kinds of composition therein,
Described Chinese medicinal composition preparation is one kind of capsule, pill, granule, tablet or oral liquid.
3. the Chinese medicine composition for the treatment of allergic rhinitis Asthma Syndrome according to claim 1, it is characterised in that described
The preparation method of granule specifically follow the steps below：
（1）Each material medicine is weighed respectively by following weight：American Ginseng 100g, HERBA EPIMEDII 200g, saline cistanche 150g, frutus cnidii
150g, fenugreek 150g, rhizoma pinellinae praeparata 250g, aster 250g, tussilago 150g, Fructus Corni 150g, windproof 150g, the achene of Siberian cocklebur
150g, flower bud of lily magnolia 250g, cassia twig 200g, root tuber of aromatic turmeric 150g, rattletop 250g, Ligusticum wallichii 150g, hairyvein agrimony 150g and radix glycyrrhizae 100g；
（2）The American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, add American Ginseng, HERBA EPIMEDII, saline cistanche,
The mass concentration of 8 times of weight of the flower bud of lily magnolia is 75% ethanol, heating and refluxing extraction 2 hours, filtering, obtains the first filtrate, the first filtrate subtracts
Receipts ethanol is pushed back, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, A liquid is made；
（3）The dregs of a decoction and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, windproof, Siberian cocklebur after ethanol is extracted
Son, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct twice,
1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, B is made
Liquid；
（4）A liquid and B liquid are mixed, are concentrated at 50 DEG C, relative density is 1.10 clear cream, adds sucrose and dextrin, is mixed,
Particle is made, dries, produces.
4. the Chinese medicine composition for the treatment of allergic rhinitis Asthma Syndrome according to claim 1, it is characterised in that described
The preparation method of tablet specifically follow the steps below：
（1）Each raw material is weighed respectively by following weight：American Ginseng 50g, HERBA EPIMEDII 400g, saline cistanche 100g, frutus cnidii 300g, Hu
Reed bar 100g, rhizoma pinellinae praeparata 400g, aster 200g, tussilago 300g, Fructus Corni 100g, windproof 300g, achene of Siberian cocklebur 100g, the flower bud of lily magnolia
400g, cassia twig 200g, root tuber of aromatic turmeric 300g, rattletop 200g, Ligusticum wallichii 300g, hairyvein agrimony 100g and radix glycyrrhizae 300g；
（2）The American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, add American Ginseng, HERBA EPIMEDII, saline cistanche,
The mass concentration of 8 times of weight of the flower bud of lily magnolia is 75% ethanol, heating and refluxing extraction 2 hours, filtering, obtains the first filtrate, the first filtrate subtracts
Receipts ethanol is pushed back, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, A liquid is made；
（3）The dregs of a decoction and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, windproof, Siberian cocklebur after ethanol is extracted
Son, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct twice,
1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, B is made
Liquid；
（4）A liquid and B liquid are mixed, are concentrated at 50 DEG C, relative density is 1.30 clear cream, adds starch and mixes, dries, powder
It is broken, talcum powder and magnesium stearate are added, mixing is tabletted, every weight 0.5g.
5. the Chinese medicine composition for the treatment of allergic rhinitis Asthma Syndrome according to claim 1, it is characterised in that institute
The preparation method for the capsule stated specifically follows the steps below：
（1）Each raw material is weighed respectively by following weight：American Ginseng 250g, HERBA EPIMEDII 200g, saline cistanche 300g, frutus cnidii 100g,
Fenugreek 300g, rhizoma pinellinae praeparata 200g, aster 400g, tussilago 100g, Fructus Corni 300g, windproof 100g, achene of Siberian cocklebur 300g, the flower bud of lily magnolia
200g, cassia twig 400g, root tuber of aromatic turmeric 100g, rattletop 400g, Ligusticum wallichii 100g, hairyvein agrimony 300g and radix glycyrrhizae 100g；
（2）The American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, add American Ginseng, HERBA EPIMEDII, saline cistanche,
The mass concentration of 8 times of weight of the flower bud of lily magnolia is 75% ethanol, heating and refluxing extraction 2 hours, filtering, obtains the first filtrate, the first filtrate subtracts
Receipts ethanol is pushed back, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, A liquid is made；
（3）The dregs of a decoction and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, windproof, Siberian cocklebur after ethanol is extracted
Son, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct twice,
1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, B is made
Liquid；
（4）A liquid and B liquid are mixed, are concentrated into the clear cream that relative density at 50 DEG C is 1.20, starch is added and mixes, dry, powder
It is broken, calcium sulfate and talcum powder are added, is mixed, particle is made, loads capsule, every weight 0.5g.
6. the Chinese medicine composition for the treatment of allergic rhinitis Asthma Syndrome according to claim 1, it is characterised in that described
The preparation method of pill specifically follow the steps below：
（1）Each raw material is weighed respectively by following weight：American Ginseng 200g, HERBA EPIMEDII 350g, saline cistanche 200g, frutus cnidii 200g,
Fenugreek 200g, rhizoma pinellinae praeparata 300g, aster 300g, tussilago 200g, Fructus Corni 250g, windproof 250g, achene of Siberian cocklebur 250g, the flower bud of lily magnolia
300g, cassia twig 300g, root tuber of aromatic turmeric 250g, rattletop 300g, Ligusticum wallichii 200g, hairyvein agrimony 250g and radix glycyrrhizae 200g；
（2）The American Ginseng, HERBA EPIMEDII, saline cistanche, the flower bud of lily magnolia that weigh up are mixed, add American Ginseng, HERBA EPIMEDII, saline cistanche,
The mass concentration of 8 times of weight of the flower bud of lily magnolia is 75% ethanol, heating and refluxing extraction 2 hours, filtering, obtains the first filtrate, the first filtrate subtracts
Receipts ethanol is pushed back, obtains decoction, and is concentrated into the 1/2-1/3 of original volume, A liquid is made；
（3）The dregs of a decoction and frutus cnidii, fenugreek, rhizoma pinellinae praeparata, aster, tussilago, Fructus Corni, windproof, Siberian cocklebur after ethanol is extracted
Son, cassia twig, root tuber of aromatic turmeric, rattletop, Ligusticum wallichii, hairyvein agrimony, radix glycyrrhizae mix, and add the water of 6 times of weight of material medicine, decoct twice,
1.5 hours every time, collecting decoction, filtering, the second filtrate is obtained, the second filtrate decompression is concentrated into the 1/2-1/3 of original volume, B is made
Liquid；
（4）A liquid and B liquid are mixed, are concentrated into the clear cream that relative density at 50 DEG C is 1.20, starch is added and mixes, dry, powder
It is broken, sucrose and talcum powder are added, mixes, pill is made, the weight 0.5g per ball.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510211910.9A CN104758860B (en) | 2015-04-28 | 2015-04-28 | A kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510211910.9A CN104758860B (en) | 2015-04-28 | 2015-04-28 | A kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104758860A CN104758860A (en) | 2015-07-08 |
| CN104758860B true CN104758860B (en) | 2018-01-19 |
Family
ID=53641176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510211910.9A Active CN104758860B (en) | 2015-04-28 | 2015-04-28 | A kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758860B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114767724A (en) * | 2022-04-26 | 2022-07-22 | 湖南中医药大学第一附属医院((中医临床研究所)) | Application of aster tataricus powder extract in preparation of medicine for treating chronic rhinitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028812A (en) * | 2010-12-16 | 2011-04-27 | 朱友文 | Chinese medicinal preparation for treating allergic rhinitis, allergic asthma and urticaria and preparation method thereof |
| CN102813904A (en) * | 2012-09-06 | 2012-12-12 | 江苏省中医院 | Compound medicine for treating anaphylactic rhinitis-asthma syndrome and preparation method and application thereof |
| CN104436145A (en) * | 2014-12-25 | 2015-03-25 | 吉林一正药业集团有限公司 | Pharmaceutical composition for preventing and/or treating allergic rhinitis and allergic asthma |
-
2015
- 2015-04-28 CN CN201510211910.9A patent/CN104758860B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028812A (en) * | 2010-12-16 | 2011-04-27 | 朱友文 | Chinese medicinal preparation for treating allergic rhinitis, allergic asthma and urticaria and preparation method thereof |
| CN102813904A (en) * | 2012-09-06 | 2012-12-12 | 江苏省中医院 | Compound medicine for treating anaphylactic rhinitis-asthma syndrome and preparation method and application thereof |
| CN104436145A (en) * | 2014-12-25 | 2015-03-25 | 吉林一正药业集团有限公司 | Pharmaceutical composition for preventing and/or treating allergic rhinitis and allergic asthma |
Non-Patent Citations (1)
| Title |
|---|
| 过敏性鼻炎—哮喘综合征中医治疗心得;方弘 等;《上海中医药杂志》;20101010;第44卷(第10期);第44页右栏第2段、第45页左栏第2-3段、第45页右栏第4-6段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104758860A (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102813904B (en) | Compound medicine for treating anaphylactic rhinitis-asthma syndrome and preparation method and application thereof | |
| CN101658631A (en) | Drug for treating chronic bronchitis and pulmonary emphysema | |
| CN105233231A (en) | Pharmaceutical composition for treating respiratory diseases | |
| CN107648468A (en) | A kind of Chinese medicine composition for treating COPD and its application | |
| CN104758860B (en) | A kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome | |
| CN102988696B (en) | Traditional Chinese medicinal composition used for treating coronary heart disease angina pectoris, and its use | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| CN113648378B (en) | Traditional Chinese medicine compound for treating early stage neocoronary pneumonia and application of traditional Chinese medicine compound for treating respiratory tract infection | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN102205044B (en) | Medicament for treating cough | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN104127544B (en) | The application in preparing medicine of Murraya tetramera Huang and extract thereof | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN105412646B (en) | A kind of Chinese medicine composition and application thereof for treating fever caused by exogenous pathogens | |
| CN104983942A (en) | Ventilating lung qi capsule and preparation method thereof | |
| CN109771632A (en) | A kind of pharmaceutical composition and its preparation method and application for treating stable phase of chronic obstructive pulmonary disease | |
| CN104013676B (en) | Buddleja officinalis and application of extract thereof in drug preparation | |
| CN104189076B (en) | A kind of Traditional Chinese medicine plaster for treating children's cold asthma and preparation method thereof | |
| CN104491637B (en) | It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN103655849B (en) | Chinese medicine composition for the treatment of anemofrigid cold and its preparation method and application | |
| CN1337252A (en) | Chinese medicine for treating chronic bronchitis | |
| CN104873743A (en) | Traditional Chinese medicine preparation for treating acute stage of chronic pulmonary heart disease and preparation method thereof | |
| CN105687684A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease | |
| CN104189288A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220721 Address after: 423000 block B, building 7, innovation and entrepreneurship Park, Linyi Avenue, bailutang Town, Suxian District, Chenzhou City, Hunan Province Patentee after: Hunan Anxing Zhengyanghe Biotechnology Co.,Ltd. Address before: 450008 No. 1 Jinshui Road, Jinshui District, Henan, Zhengzhou Patentee before: HENAN University OF Chinese Medicine |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231107 Address after: Room 1015, Shuangta International Plaza Building, No. 258, Section 2, Xiangfu East Road, Yuhua District, Changsha City, Hunan Province, 410000 Patentee after: Hunan Anxiang Zhengyang He Network Technology Co.,Ltd. Address before: 423000 block B, building 7, innovation and entrepreneurship Park, Linyi Avenue, bailutang Town, Suxian District, Chenzhou City, Hunan Province Patentee before: Hunan Anxing Zhengyanghe Biotechnology Co.,Ltd. |